Table 1.
Demographic and baseline characteristics of the patients (n = 11,312)
| Variable | Baseline values |
|---|---|
| Age (years) | |
| Mean age (SD) | 58.4 (13.8) |
| Patients in each group, n (%) | |
| <65 | 7,677 (67.9) |
| 65–<80 | 2,863 (25.3) |
| ≥80 | 746 (6.6) |
| Gender, n (%) | |
| Male | 6,456 (57.1) |
| Mean height (SD), cm | 167.15 (7.8) |
| Mean weight (SD), kg | 69.18 (11.4) |
| Mean waistline (SD), cm | |
| Female | 82.1 (11.0) |
| Male | 89.3 (10.4) |
| Ethnicity, n (%) | |
| Han | 10,989 (97.1) |
| BMI (kg/m2) | |
| Mean BMI (SD) | 24.7 (3.2) |
| Patients in each group, n (%) | |
| Underweight (BMI <19) | 266 (2.4) |
| Normal (19 ≤ BMI < 24) | 4,449 (39.3) |
| Overweight (24 ≤ BMI < 28) | 5,127 (45.3) |
| Obese (BMI >28) | 1,447 (12.8) |
| Present cardiovascular risk factors/medical history, n (%) | |
| Dyslipidemia | 2,702 (23.9) |
| Diabetes | 1,865 (16.5) |
| CHD | 1,753 (15.5) |
| HF | 189 (1.7) |
| Stroke | 591 (5.2) |
| Kidney disease | 355 (3.1) |
| BP data (mmHg) | |
| Mean baseline SBP | 159.6 |
| Mean baseline DBP | 95.6 |
| Patients in each SBP group (n, %) | |
| <140 | 184 (1.6) |
| 140–159 | 5,398 (47.7) |
| 159–180 | 4,816 (42.6) |
| ≥180 | 914 (8.1) |
| Previous antihypertensive drug classes, n (%) | |
| β-Blockers | 903 (7.99) |
| CCBs | 5,413 (47.90) |
| ACEIs | 1,728 (15.29) |
| Diuretics | 321 (2.84) |
| ARB | 2,853 (25.2) |
| Others | 82 (0.73) |
| Unknown | 12 (0.11) |
ACEIs angiotensin-converting enzyme inhibitors, ARBs angiotensin-II receptor blockers, BMI body mass index, BP blood pressure, CCBs calcium channel blockers, CHD chronic heart disease, DBP diastolic blood pressure, HF heart failure, SBP systolic blood pressure